Our December 16, 2024 Investors Webinar – Expectations 2025 – was well attended and well received.  We thank and welcome all of our new investors, including our first fund.  

During the webinar, Michael Tierney, the Company’s co-founder and CEO, covered the planned 2025 acceleration of its 2024 market traction.  As he explained, the demand for Circles real-world evidence datasets is likely to expand significantly in the coming years.

As a “Zero-To-One” company with growing recurring revenues, RegenMed is focused on rapid scaling within its large markets.  While not specifying current Company valuations, Mr. Tierney discussed the rapid growth in recurring revenues and corresponding market value of several other SaaS companies.

Mr. Tierney also identified strategic exits of relevant healthcare data companies at large valuations.  These included CorEvitas, acquired by Thermo Fisher for $913 million in cash in 2023.  Like RegenMed, CorEvitas focuses on real-world evidence.

Mr. Tierney reviewed as an example of the Company’s progress the enthusiastic adoption of Physicians-Owned Circles commencing in the fourth quarter of 2024.

The Company is preparing a series of YouTube videos covering major topics presented during the December 16 webinar.  Once published, these will also be available on the Company’s Investors Page, with links also provided in future StartEngine campaign page updates.

_{This Reg CF offering is made available through StartEngine Primary LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.}